Metformin controlled release - HanAll Biopharma

Drug Profile

Metformin controlled release - HanAll Biopharma

Alternative Names: Glucodown OR; Glucodown OR sustained-release tablets - HanAll; HL-018; HL001; HL002; Metformin 500mg + 750mg optimised release tablets - HanAll; Metformin OR tablets - HanAll

Latest Information Update: 30 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HanAll Biopharma
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus
  • Preclinical Obesity

Most Recent Events

  • 30 Oct 2018 HL 018 is still in preclinical trials for Obesity in South Korea (Hanall Biopharma pipeline, October 2018)
  • 15 Mar 2016 Biomarkers information updated
  • 14 Aug 2015 Preclinical trials in Obesity in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top